“Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s365. doi:10.25251/skin.8.supp.365.